GERMANTOWN, Md., Sept. 24, 2019 /PRNewswire/ -- Neuralstem, Inc.
(Nasdaq:CUR), a biopharmaceutical company focused on developing
novel treatments for nervous system diseases, announced completion
of subject enrollment in its Phase 2 clinical trial of NSI-566 for
the treatment of chronic ischemic stroke. NSI-566 is
Neuralstem's lead stem cell therapy candidate, and has also been
evaluated in clinical trials for patients with Amyotrophic Lateral
Sclerosis and chronic spinal cord injury. The trial is being
conducted at the BaYi Brain Hospital (affiliated to the
7th Medical Center of the PLA General Hospital) in
Beijing, China under the direction
of Professor Xu Ruxiang.
"Completing the subject enrollment in this Phase 2 study is an
important clinical milestone for Neuralstem," said Dr. Ken Carter, Executive Chairman of Neuralstem.
"We expect results from this study in the second half of 2020 and
are thankful to the individuals and physicians who are
participating."
The double-blind, placebo-controlled study enrolled 22 subjects
that were randomized to one of two groups: a treatment group that
received intracerebral administration of 72 million human neural
stem cells or a sham surgery group. Subjects enrolled in the study
were to have sustained chronic motor deficits due to an ischemic
stroke 4-24 months prior to enrollment, and will be evaluated for
measures of efficacy for 12 months after surgery and measures of
safety for an additional 48 months.
About Ischemic Stroke
Ischemic stroke, the most common type of stroke, occurs as a
result of an obstruction within a blood vessel supplying blood to
the brain. Approximately 15 million people worldwide suffer stroke,
of which approximately 87% are ischemic strokes. Post-stroke motor
deficits include paralysis in arms and legs and can be
permanent.
About Neuralstem
Neuralstem is a clinical-stage biopharmaceutical company
developing novel treatments for nervous system diseases of high
unmet medical need. The Company has two lead development
candidates:
- NSI-566 is a stem cell therapy being tested for treatment of
paralysis in stroke, Amyotrophic Lateral Sclerosis (ALS) and
chronic spinal cord injury (cSCI)
- NSI-189, is a small molecule in clinical development for major
depressive disorder and in preclinical development for Angelman
syndrome, irradiation-induced cognitive impairment, diabetic
neuropathy, and stroke
Neuralstem's diversified portfolio of product candidates is
based on its proprietary neural stem cell technology.
Cautionary Statement Regarding Forward Looking
Information
This news release contains "forward-looking statements" made
pursuant to the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements
relate to future, not past, events and may often be identified by
words such as "expect," "anticipate," "intend," "plan," "believe,"
"seek" or "will." Forward-looking statements by their nature
address matters that are, to different degrees, uncertain. Specific
risks and uncertainties that could cause our actual results to
differ materially from those expressed in our forward-looking
statements include risks inherent in the development and
commercialization of potential products, uncertainty of clinical
trial results or regulatory approvals or clearances, need for
future capital, dependence upon collaborators and maintenance of
our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed
from time to time in Neuralstem's periodic reports, including the
Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and
Exchange Commission (SEC), and in other reports filed with the SEC.
We do not assume any obligation to update any forward-looking
statements.
Contact:
Josh Barer
Hibiscus BioVentures
josh@hibiscusbio.com
View original
content:http://www.prnewswire.com/news-releases/neuralstem-announces-last-subject-enrolled-in-phase-2-clinical-trial-evaluating-human-neural-stem-cells-in-chronic-stroke-patients-300922864.html
SOURCE Neuralstem, Inc.